Memantine versus Methylphenidate in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial
AbstractObjectives: The aim of this randomized clinical trial was to assess the efficacy of memantine versus methylphenidate in the treatment of children with attention deficit hyperactivity disorder.Method: Forty participants (34 boys and 6 girls) aged 6-11 who were diagnosed with attention deficit hyperactivity disorder based on (DSM-IV-TR) criteria were selected for this study. The participants were randomly assigned to two groups: group one (n = 22) received memantine and the other group (n = 18) received methylphenidate for six weeks. Treatment outcomes were assessed using the Attention Deficit Hyperactivity Rating Scale and Clinical Global Impression- Severity Scale administered at baseline and at weeks 3 and 6 following the treatment. Also, a two-way repeated measures analysis of variance (time- treatment interaction) was used.Results: At 6 weeks, methylphenidate produced a significantly better outcome on the Parent Rating Scale scores and Clinical Global Impression- Severity than memantine. Side effects were observed more often in the memantine group. However, with respect to the frequency of side effects, the difference between the memantine and methylphenidate groups was not significant. The most common side effects associated with memantine are appetite suppression, headache, vomiting, nausea and fatigue.Conclusion: The results of this study revealed that although memantine was less effective than methylphenidate in the treatment of attention deficit hyperactivity disorder, it may be considered as an alternative treatment.
American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders, 4th Ed (DSM-IV). Washington, DC: American Psychiatric Association, 1994.
Galili-Weisstub E, Segman RH. Attention deficit and hyperactivity disorder: Review of genetic association studies. Isr J Psychiatry Relat Sci, 2003; 40: 57–66.
Richard, W, Root II, Robert J, Resnick J. An update on the diagnosis and treatment of attention-deficit/hyperactivity disorder in children. Professional Psychological Research and Practice 2003; 34: 34–41.
Swanson JM, McBurnett K, Wigal T, Pfiffner LJ, Lerner MA, Williams L, Christian DL, Tamm L, Willcutt E, Crowley K, Clevenger W, Khouzam N, Woo C, Crinella FM, Fisher TD. Effect of stimulant medication on children with attention deficit disorder: A review of reviews. Except Child, 1993; 60:154–162.
Swanson JM, Lerner M, Williams L. More frequent diagnosis of attention deficit hyperactivity disorder. N Engl J Med 1995; 333:944.
James RS, Sharp WS, Bastain TM, Lee PP, Walter JM, Czarnolewski M, Castellanos FX. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiatry 2001; 40:1268–1276.
Pelham WE Jr, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, Guthrie KJ, Hoover MD, Dahl RE: Relative efficacy of long-acting stimulants on children with attention deficit hyperactivity disorder: A comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 1990; 86: 226–237.
Greenhill LL, Findling RL, Swanson JM. A double -blind, placebo-controlled study of modified-release methylphenidate in children with attention deficit hyperactivity disorder. Pediatrics 2002; 109: E39.
Greenhill LL, Abikoff HB, Arnold LE, Cantwell DP, Conners CK, Elliott G, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, March JS, Newcorn J, Pelham WE, Severe JB, Swanson JM, Vitiello B, and Wells K: Medication treatment strategies in the MTA study: Relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1996; 35:1304–1313.
Greenhill LL, and Osman, BB, eds. Ritalin: Theory and practice (2nd ed.). Journal of Child Psychology and Psychiatry, October 2000; 41: 949-952.
Klein RG. Clinical efficacy of methylphenidate in children and adolescents. Encephale 1993; 19:89–93.
Barkley RA: A review of stimulant drug research with hyperactive children to stimulant drugs: A review. J Child Psychol Psychiatry, 1977; 18: 137–165.
Lewis M ed. Child and adolescent psychiatry (3rd ed.). Philadelphia: Lippincott Williams and Wilkins, 2002.
Kaplan HI, Sadock BJ eds. Synopsis of psychiatry: Behavioral sciences/clinical psychiatry 9th eds. Philadelphia: Lippincott Williams & Wilkins; 2003.
Cyr M, Brown CS. Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder 1998; Drugs 56:215–223.
Sallee F, Connor DF, Newcorn JH. A Review of the Rationale and Clinical Utilization of α2- Adrenoceptor Agonists for the Treatment of Attention-Deficit/Hyperactivity and Related Disorders. Child Adolesc Psychopharmacology. 2013; 23: 308-319.
Silver LB. Alternative (nonstimulant) medications in the treatment of attention deficit hyperactivity disorder in children. Pediatr Clin North Am 1999; 46: 965–975.
Amiri S, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Kahbazi M, Akhondzadeh S. Modafinil as a treatment for attention-deficit/hyper- activity disorder in children and adolescents: a double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 145–149.
Mohammadi MR, Kazemi MR, Zia E, Rezazadeh SA, Tabrizi M, Akhondzadeh S. Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial, human psychopharmacology Hum. Psychopharmacol Clin Exp, 2010; Published online in Wiley Online Library (wileyonlinelibrary.com) DOI.
Mohammadi MR, Ghanizadeh A, Alaghband-Rad J, Tehranidoost M, Mesgarpour B, Soori H.Selegiline in Comparison with Methylphenidate in Attention Deficit Hyperactivity Disorder Children and Adolescents in a Double-Blind, Randomized Clinical Trial M.D., Journal Of Child And Adolescent Psychopharmacology 2004; 14: 418–425.
Zarinara AR, Mohammadi MR, Hazrati N, Tabrizi M, Rezazadeh SA, Rezaie F,Akhondzadeh S. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Hum Psychopharmacol. 2010 Nov; 25: 530-535.
Kehoe WA. Treatment of attention deficit hyperactivity disorder in children. Ann Pharmacother 2001; 35: 1130–1134.
Carlsson M. On the role of cortical glutamine in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions. Acta Psychiatrica Scandinavica, 2000; 102: 401–413.
Carrey N, MacMaster FP, Fogel J, Sparkes S,Waschbusch D, Sullivan S, Schmidt M: Metabolite changes resulting from treatment in children with ADHD: A 1H-MRS study. Clin Neuropharmacol 2003; 26: 218–221.
Kavirajan H. Memantine: A comprehensive review of safety and efficacy. Drug Safety Evaluation 2009; 8: 89–109.
Carrey N, MacMaster F, Gaudet L, Schmidt M. Striatal creatine and glutamate/glutamine in attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 2007; 17: 11–17.
Kotecha SA, Oak JN, Jackson MF, Perez Y, Orser BA, Van Tol HH, and MacDonald JF: AD2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. Neuron 2002; 35: 1111–1122.
Turic D, Langley K, Mills’ S, Stephens M, Lawson D, Govan C, et al. Follow-up of genetic linkage findings on chromosome 16p13: Evidence of association of N-methyl-D-aspartate glutamate receptor 2A gene polymorphism with ADHD. Mol Psychiatry 2004; 9:169–173.
Winblad B, Poritis N: Memantine in severe dementia: results of the M-BEST Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135–146.
Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ: Memantine in moderate-to-severe Alzheimer ’s disease. N Engl J Med 2003; 348: 1333–1341.
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I: Memantine treatment in patients with moderate to severe Alzheimer disease treatment with memantine). Int J Geriatr Psychiatry ,1999;14:135–146.
Kornhuber J, Quack G: Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 1995; 195: 137–139.
Periclou AP, Ventura D, Sherman T, Rao N, Abramowitz WT: Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother 2004; 38:1389–1394.
Periclou A, Ventura D, Rao N, Abramowitz W: Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther 2006; 79:134–143.
Forest Pharmaceuticals: Namenda® (memantine hydrochloride) prescribing information. St. Louis (Missouri), Forest Laboratories, Inc 2005.
Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F: Efficacy and safety of memantine in pa- tients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33:1834–1839.
Wilcock G, Möbius HJ, Stöffler A: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002; 17: 297–305.
Sadock, Benjamin J, Sadock, Virginia A, Ruiz, Pedro.Kaplan, Sadock's Comprehensive Textbook of Psychiatry. 9th Edition. 2009 Lippincott Williams & Wilkins. P.3098.
Rabert L, Findling MD, et al. A Pilot Evaluation of the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Memantinein Pediatric Patients with Attention-Deficit Hyperactivity Disorder Combined Type. Journal of child and adolescent Psychopharmacology, 2007 Feb;17: 19-33.
Surman CB, Hammerness PG, Petty C, Spencer T, Doyle R, Napolean S, Chu N, Yorks D, Biederman J. A pilot open label prospective study of memantine monotherapy in adults with ADHD. World J Biol Psychiatry 2013; 14: 291-8.
American Psychiatric Association, Diagnostic and Statistical Manual for Mental Disorders DSM IV-TR, 4th edn (Text Revision). American Psychiatric Press: Washington DC; 2000.
Ghanizadeh A, Mohammadi MR, Yazdanshenas A. Psychometric properties of the Farsi translation of the Kiddie Schedule for Affective Disorders and Schizophrenia – present and lifetime version. BMC Psychiatry, 2006; 15: 10.
DuPaul G, Power T, Anastopoulos A, Reid R. ADHD Rating Scale-IV. Guilford: New York; 1998.
Akhondzadeh S, Mohammadi MR, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyper- activity disorder in children: a double blind and randomized trial .BMC Psychiatry 2004; 8: 9.
Akhondzadeh S, Tavakolian R, Davari-Ashtiani R, Arabgol F, Amini H. Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 841-845.
Kahbazi M, Ghoreishi A, Rahiminejad F, Mohammadi MR, Kamalipour A, Akhondzadeh S. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Res 2009; 168: 234–237.
Guy W: ECDEU Assessment Manual for Psychopharmacology —Revised (DHEW Publ No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs 1976; 218–222.
Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy 2009; 29: 656–679.
Chavez B, Sopko MA, Jr., Ehret MJ, et al. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. Ann Pharmacother 2009; 43: 1084-1095.
Sadock, Benjamin J, Sadock, Virginia A, Ruiz, Pedro.Kaplan, Sadock's Comprehensive Textbook of Psychiatry. 9th Edition. 2009 Lippincott Williams & Wilkins. P.3563
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry, 2007; 164: 942–948.
Noorbala AA, Akhondzadeh S. Attention-deficit/hyperactivity disorder:etiology and pharmacotherapy. Archives of Iranian Medicine 2006; 9: 374–380.
Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004; 13 Suppl 1: I102-16.
Rains A, Scahill L, Hamrin V. Nonstimulant medications for the treatment of ADHD. J Child Adolesc Psychiatr Nurs 2006; 19: 44–47.
Mohammadi MR, Akhondzadeh S. Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. Expert Rev Neurother. 2007; 7: 195-201.
J Adams, J Crosbie; et al. Glutamate receptor, ionotropic, N-methyl D-aspartate 2A (GRIN2A) gene as a positional candidate for attention-deficit/hyperactivity disorder in the 16p13 region. Molecular Psychiatry 2004; 9: 494–499.